Ashley Marie Regazzi

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

1.8Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1283

Top 12%

1.8DataRank

Top 12%68 citations

Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more

Papers

Driven by 19 papers — median percentile 88. Top paper: “Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial”.

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.01485

N/A

3.3DataRank · unranked

100 citations

Michael Lattanzi, Karissa Whiting, Hikmat Al‐Ahmadie, Colleen Quinlan, Min Yuen Teo +34 more

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

Nature Communications(2022)10.1038/s41467-022-29342-0

N/A

2.1DataRank · unranked

82 citations

Samuel A. Funt, Annie Borch, Kamilla Kjærgaard Munk, Anne-Mette Bjerregaard, James L. Reading +17 more

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1283

Top 12%

1.8DataRank

Top 12%68 citations

Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

British Journal of Cancer(2021)10.1038/s41416-020-01244-2

N/A

1.6DataRank · unranked

40 citations

Hikmat Al‐Ahmadie, Kenneth Seier, Christopher Tully, Ashley Marie Regazzi, Eugene J. Pietzak +15 more

Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.05.005

N/A

0.937DataRank · unranked

33 citations

Brendan J. Guercio, Arshi Arora, Xueli Hao, Ashley Marie Regazzi, Timothy F. Donahue +25 more

Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2574

N/A

0.241DataRank · unranked

4 citations

Christopher A. Desjardins, Paul A. Giardina, Kankana Bardhan, Swarna Pandian, Keith Halley +14 more

Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)

European Urology Open Science(2025)10.1016/j.euros.2025.03.009

N/A

0.208DataRank · unranked

3 citations

Karissa Whiting, Ronak Shah, Karla V. Ballman, Susan Halabi, Ashley Marie Regazzi +10 more

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4562

N/A

0.104DataRank · unranked

1 citations

Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat Al‐Ahmadie, Jonathan E. Rosenberg +12 more

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4598

N/A

0DataRank · unranked

2 citations

Neha Ratna, David Gavrilov, Cihan Düzgöl, Mahnoor Akhlaq, Min Yuen Teo +15 more

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma

UNC Libraries(2024)10.17615/6gs3-hm85

N/A

0DataRank · unranked

0 citations

Irina Ostrovnaya, Matthew I. Milowsky, Jonathan E. Rosenberg, Wassim Abida, Dean F. Bajorin +6 more

Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2020.02.014

N/A

0DataRank · unranked

46 citations

Christopher Tully, Emily C. Zabor, Bernard H. Bochner, Guido Dalbagni, Harry W. Herr +8 more

A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.264

N/A

0DataRank · unranked

0 citations

Jessica Flynn, Binsheng Zhao, Aseem Anand, Karl Sjöstrand, Steven M. Larson +7 more

Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2020.12.002

N/A

0DataRank · unranked

2 citations

Darren R. Feldman, Michael J. Morris, Robert J. Motzer, Dana E. Rathkopf, Ashley Marie Regazzi +5 more

Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e16519

N/A

0DataRank · unranked

0 citations

Min Yuen Teo, Samuel A. Funt, Chung‐Han Lee, David H. Aggen, Neha Ratna +11 more

Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.498

N/A

0DataRank · unranked

12 citations

Eugene J. Pietzak, Samantha Brown, Jie‐Fu Chen, Vanessa Peters, Ashley Marie Regazzi +15 more

Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4522

N/A

0DataRank · unranked

5 citations

Catherine M. Tangen, Michal Sarfaty, Ashley Marie Regazzi, I-Ling C. Lee, Woonyoung Choi +6 more

Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4584

N/A

0DataRank · unranked

2 citations

Alexander Solovyov, Jayon Lihm, Colleen Quinlan, Karissa Whiting, Hao Li +15 more

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4521

N/A

0DataRank · unranked

0 citations

Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat Al‐Ahmadie +12 more

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade

Journal of Clinical Oncology(2023)10.1200/jco.22.02144

N/A

0DataRank · unranked

18 citations

Mahdi Golkaram, Samuel A. Funt, Hikmat Al‐Ahmadie, Shannon Kaplan, Fan Song +11 more

Ashley Marie Regazzi

Indexed papers

Top data-sharing exemplar

Papers